Cargando…

Bromodomain Blockade for Intimal Hyperplasia — A Good BET?

Detalles Bibliográficos
Autores principales:	Ostriker, Allison C., Martin, Kathleen A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740337/ https://www.ncbi.nlm.nih.gov/pubmed/26870770 http://dx.doi.org/10.1016/j.ebiom.2015.11.007

Ejemplares similares

BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries
por: Wang, Bowen, et al.
Publicado: (2015)

Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010)

Targeting BET bromodomain proteins in solid tumors
por: Sahai, Vaibhav, et al.
Publicado: (2016)

Chemical probes and inhibitors of bromodomains outside the BET family
por: Moustakim, Moses, et al.
Publicado: (2016)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Selective BET bromodomain inhibition as an antifungal therapeutic strategy
por: Mietton, Flore, et al.
Publicado: (2017)

Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains
por: Lambert, Jean-Philippe, et al.
Publicado: (2019)

BET bromodomain proteins are required for glioblastoma cell proliferation
por: Pastori, Chiara, et al.
Publicado: (2014)

When are the BET factors the most sensitive to bromodomain inhibitors?
por: Khochbin, Saadi
Publicado: (2013)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
por: Mao, Wendy, et al.
Publicado: (2019)

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
por: Taniguchi, Yasushi
Publicado: (2016)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
por: To, Kenneth K. W., et al.
Publicado: (2023)

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013)

Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor
por: Dutra, Luiz Antonio, et al.
Publicado: (2017)

BET bromodomain inhibition suppresses T(H)17-mediated pathology
por: Mele, Deanna A., et al.
Publicado: (2013)

BET bromodomain proteins regulate enhancer function during adipogenesis
por: Brown, Jonathan D., et al.
Publicado: (2018)

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023)

Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors
por: Flynn, Noah R., et al.
Publicado: (2021)

Optimization of a “bump-and-hole” approach to allele-selective BET bromodomain inhibition
por: Runcie, A. C., et al.
Publicado: (2018)

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
por: Fu, Lei-lei, et al.
Publicado: (2015)

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
por: Nguyen, Martin V., et al.
Publicado: (2020)

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
por: Wyce, Anastasia, et al.
Publicado: (2013)

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)

Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer
por: Asangani, Irfan A., et al.
Publicado: (2014)

Response and resistance to BET bromodomain inhibitors in triple negative breast cancer
por: Shu, Shaokun, et al.
Publicado: (2016)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
por: Filippakopoulos, Panagis, et al.
Publicado: (2012)

Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability
por: Lori, Laura, et al.
Publicado: (2016)

Bromodomain Inhibitors as Therapeutics for Herpesvirus-Related Disease: All BETs Are Off?
por: Groves, Ian J., et al.
Publicado: (2020)

BET Bromodomain Inhibitors and Pulmonary Arterial Hypertension: Take Care of the Heart
por: Piquereau, Jérôme, et al.
Publicado: (2019)

Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
por: Trivedi, Archit, et al.
Publicado: (2020)

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
por: Wang, Zhi-Qiang, et al.
Publicado: (2023)

Discovery of Benzo[d]imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
por: Cipriano, Alessandra, et al.
Publicado: (2022)

Bromodomain AAA+ ATPases get into shape
por: Murawska, Magdalena, et al.
Publicado: (2020)

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma
por: Funck-Brentano, Elisa, et al.
Publicado: (2020)

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
por: McLure, Kevin G., et al.
Publicado: (2013)

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
por: Díaz, Tania, et al.
Publicado: (2017)

The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats
por: Piquereau, Jérôme, et al.
Publicado: (2019)

Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition
por: Tang, Yujie, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0gun18h8j9mvus2ad0tjrv0cb5